News & Press Releases

 

Robert Jacks Robert Jacks

Sparrow Pharmaceuticals Collaborates with the University of Oxford and the University of Sheffield on DC-MACS, a Phase 2 Clinical Study of Clofutriben for Autonomous Cortisol Secretion

Sparrow Pharmaceuticals is collaborating with the University of Oxford and the University of Sheffield on DC-MACS, an investigator led, Phase 2 clinical study in the United Kingdom of clofutriben (SPI-62) for the treatment of autonomous cortisol secretion (ACS).

Read More
Robert Jacks Robert Jacks

Sparrow Pharmaceuticals to Present Two Abstracts at ACR Convergence 2024 and Expand Phase 2 Clinical Trial of Clofutriben with Prednisolone for Polymyalgia Rheumatica to Fifth Cohort

Sparrow Pharmaceuticals will present interim data from the ongoing Phase 2 trial of lead agent clofutriben in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) at the American College of Rheumatology Convergence 2024 conference. Sparrow also announced that the trial has been expanded with a fifth cohort based on encouraging results from the first four cohorts.

Read More
Robert Jacks Robert Jacks

Sparrow Pharmaceuticals Presents Novel Data on Clofutriben (SPI-62) Reducing Glucocorticoid Toxicities with a Low Risk of Adrenal Insufficiency at the 2024 Annual Endocrine Society Conference

Sparrow Pharmaceuticals announced today that, to date, the HSD-1 inhibitor clofutriben (SPI-62) has normalized urine free cortisol (UFC) in >60% of patients with endogenous Cushing’s syndrome (EnCS) without suppressing serum cortisol to levels considered to indicate risk for adrenal insufficiency (AI).

Read More
Robert Jacks Robert Jacks

Sparrow Pharmaceuticals Announces First Patient Rolled-Over to Open-Label Extension of RESCUE, a Phase 2 Clinical Trial of SPI-62 for ACTH-Dependent Cushing’s Syndrome

Sparrow Pharmaceuticals today announced the first patient has elected to enroll in the open-label extension (OLE) phase of the RESCUE trial, a phase 2 clinical trial of SPI-62 for the treatment of ACTH-dependent Cushing’s syndrome. The long-term OLE will be open to patients who complete the initial RESCUE cross-over treatment protocol and then elect to continue to participate in the research.

Read More